Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 3 for:    cm24
Previous Study | Return to List | Next Study

A Study of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04731467
Recruitment Status : Recruiting
First Posted : February 1, 2021
Last Update Posted : March 29, 2021
Sponsor:
Collaborator:
Bristol-Myers Squibb
Information provided by (Responsible Party):
Purple Biotech Ltd. ( Famewave Ltd. )

Tracking Information
First Submitted Date  ICMJE January 24, 2021
First Posted Date  ICMJE February 1, 2021
Last Update Posted Date March 29, 2021
Actual Study Start Date  ICMJE March 19, 2021
Estimated Primary Completion Date February 2024   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: January 28, 2021)
  • Part A: Incidence of treatment emergent adverse events [ Time Frame: Up to 24 months ]
    Incidence of treatment emergent adverse events with CM-24 and nivolumab in adults with selected recurrent or metastatic solid tumors
  • Part B: Objective Response Rate [ Time Frame: Up to 24 months ]
    Objective Response Rate when phase 2 dose of CM-24 is used in combination with nivolumab in adults with recurrent and/or metastatic non-small cell lung cancer
  • Part C: Objective Response Rate [ Time Frame: Up to 24 months ]
    Objective Response Rate when phase 2 dose of CM-24 is used in combination with nivolumab and nab-paclitaxel in adults with metastatic pancreatic cancer
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: January 28, 2021)
  • Maximum serum concentration [Cmax] [ Time Frame: Up to 24 months ]
    Maximum serum concentration [Cmax] of CM24
  • Time of maximum concentration [Tmax] [ Time Frame: Up to 24 months ]
    Time of maximum concentration [Tmax] of CM24
  • Area under the serum concentration curve [AUC] [ Time Frame: Up to 24 months ]
    Area under the serum concentration curve [AUC] of CM24
  • Half life [ Time Frame: Up to 24 months ]
    Half life of CM24
  • Drug clearance [ Time Frame: Up to 24 months ]
    Drug clearance of CM24
  • Volume of distribution [ Time Frame: Up to 24 months ]
    Volume of distribution of CM24
  • Serum ADA parameters [ Time Frame: Up to 24 months ]
    Serum ADA parameters of CM24 as measured by percentage of patients who are positive for the presence of anti-drug antibodies
  • Objective Response Rate when CM24 is used in combination with nivolumab [ Time Frame: Up to 24 months ]
  • Disease Control Rate when CM24 is used in combination with nivolumab [ Time Frame: Up to 24 months ]
  • Median Duration of Response when CM24 is used in combination with nivolumab [ Time Frame: Up to 24 months ]
  • Median Time to Response when CM24 is used in combination with nivolumab [ Time Frame: Up to 24 months ]
  • Progression Free Survival when CM24 is used in combination with nivolumab [ Time Frame: Up to 48 months ]
  • Overall Survival when CM24 is used in combination with nivolumab [ Time Frame: Up to 48 months ]
  • Population pharmacokinetics when CM24 is used in combination with nivolumab as measured by the maximum plasma concentration [Cmax] [ Time Frame: Up to 24 months ]
  • Population pharmacokinetics when CM24 is used in combination with nivolumab as measured by the average area under the concentration curve [AUC] [ Time Frame: Up to 24 months ]
  • Population pharmacokinetics when CM24 is used in combination with nivolumab as measured by the median area under the concentration curve [AUC] [ Time Frame: Up to 24 months ]
  • Population pharmacokinetics when CM24 is used in combination with nivolumab and nab-paclitaxel as measured by the maximum plasma concentration [Cmax] [ Time Frame: Up to 24 months ]
  • Population pharmacokinetics when CM24 is used in combination with nivolumab and nab-paclitaxel as measured by the average area under the concentration curve [AUC] [ Time Frame: Up to 24 months ]
  • Population pharmacokinetics when CM24 is used in combination with nivolumab and nab-paclitaxel as measured by the median area under the concentration curve [AUC] [ Time Frame: Up to 24 months ]
  • Disease Control Rate when CM24 is used in combination with nivolumab and nab-paclitaxel [ Time Frame: Up to 24 months ]
  • Duration of Response when CM24 is used in combination with nivolumab and nab-paclitaxel [ Time Frame: Up to 24 months ]
  • Time to Response when CM24 is used in combination with nivolumab and nab-paclitaxel [ Time Frame: Up to 24 months ]
  • Progression Free Survival when CM24 is used in combination with nivolumab and nab-paclitaxel [ Time Frame: Up to 48 months ]
  • Overall Survival when CM24 is used in combination with nivolumab and nab-paclitaxel [ Time Frame: Up to 48 months ]
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A Study of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors
Official Title  ICMJE A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors
Brief Summary This is an open-label, multicenter, multi-dose escalation and dose expansion study in subjects with selected advanced solid tumors (Part A), advanced recurrent immune checkpoint refractory non-small cell lung cancer (NSCLC) (Part B), and metastatic pancreatic cancer (Part C) to evaluate the safety and tolerability of CM-24 in combination with nivolumab. In Part C of the study nab-paclitaxel will be administered subsequent to CM24 and nivolumab.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Phase 2
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Solid Tumor
  • Non Small Cell Lung Cancer
  • Pancreatic Cancer
  • Ovarian Cancer
  • Papillary Thyroid Cancer
  • Melanoma
  • Colorectal Adenocarcinoma
Intervention  ICMJE
  • Drug: CM-24 and Nivolumab - Dose Escalation
    Dose escalation of CM24 with nivolumab in adult subjects with selected recurrent or metastatic solid tumors
  • Drug: CM-24 and Nivolumab - Expansion
    Expansion cohort of CM24 in combination with nivolumab in adult subjects with recurrent or metastatic immune checkpoint refractory non-small cell lung cancer
  • Drug: CM-24, Nivolumab, and Nab paclitaxel - Expansion
    Expansion cohort of CM24 in combination with nivolumab and nab-paclitaxel in adult patients with metastatic pancreatic cancer
Study Arms  ICMJE
  • Experimental: Dose escalation of CM24 in combination with nivolumab
    Intervention: Drug: CM-24 and Nivolumab - Dose Escalation
  • Experimental: Expansion cohort of CM24 in combination with nivolumab
    Intervention: Drug: CM-24 and Nivolumab - Expansion
  • Experimental: Expansion cohort of CM24 in combination with nivolumab and nab-paclitaxel
    Intervention: Drug: CM-24, Nivolumab, and Nab paclitaxel - Expansion
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: January 28, 2021)
74
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE March 2024
Estimated Primary Completion Date February 2024   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Part A: Previously treated subjects with recurrent and/or metastatic NSCLC, pancreatic cancer, ovarian cancer, papillary thyroid cancer, colorectal adenocarcinoma and melanoma with documented progression/intolerance following at least one previous therapy (and not more than 2 previous regimens);
  2. Part B: Subjects with histologically confirmed metastatic or locally advanced non-small cell lung cancer (NSCLC) with documented progression following anti-PD-1/PD-L1 containing therapy; Subjects must have confirmation of progression of disease that is consistent with iCPD during or within 3 months of prior anti-PD1/PDL1 with either two radiographic scans showing disease progression or documented clinical progression (e.g., worsening of symptoms); Subjects could have had a maximum of 1 prior treatment regimen;
  3. Part C: Subjects with histologically confirmed metastatic pancreatic adenocarcinoma as defined by NCCN Guidelines; Subjects with islet cell neoplasms are excluded; Subjects could have had a maximum of 1 prior treatment regimen for metastatic disease excluding nab-paclitaxel containing regimens and up to 8 weeks from last chemotherapy treatment; nab-paclitaxel completed more than 6 months prior to study is allowed.
  4. Must have at least 1 measurable lesion per RECIST1.1 with progressing or new tumors since last antitumor therapy;
  5. ECOG performance status score of 0 or 1;
  6. Adequate safety lab results;
  7. Stable brain metastases;
  8. WCBP (Women of Childbearing Potential) must have a negative serum pregnancy test at Screening and a negative urine pregnancy test, WCBP must agree to abstain from sex or use an adequate method of contraception, males must abstain from sex with WCBP or use an adequate method of contraception.

Exclusion Criteria:

  1. Part A: Received more than two prior systemic regimens for the metastatic disease
  2. Part B and C: Received more than 1 prior systemic regimens for the advanced/recurrent and/or metastatic disease
  3. History of weight loss >10% over the 2 months prior to Screening;
  4. Concurrent malignancy requiring treatment;
  5. Active, untreated central nervous system (CNS) metastases;
  6. Subjects previously treated with an anti PD-1/PD-L1 targeting agent with history immune mediated toxicity;
  7. Severely immunocompromised;
  8. History of allergy or hypersensitivity to any of the study treatment components;
  9. Major surgery within 4 weeks of study administration;
  10. Clinically relevant serious co-morbid medical conditions including, but not limited to:

    • Active infection;
    • Recent (within six months of Screening) cardiac disease, myocardial infarction, or severe or unstable angina;
    • History of serious arrhythmia;
    • Chronic obstructive or chronic restrictive pulmonary disease, pulmonary hypertension history of or active interstitial lung disease or pneumonitis;
    • Prior organ allograft;
    • Subjects with active, known or suspected autoimmune disease;
    • History of active or latent tuberculosis infection;
    • Positive test for HIV, HBV, or HCV;
  11. Radiation within two weeks prior to the first study treatment;
  12. Treatment with another investigational therapy within 30 days or 5 half-lives of the drug prior to Screening, whichever is longer;
  13. Treatment with botanical preparations (e.g., herbal supplements or traditional Chinese medicines) intended for general health support or to treat the disease under study within 2 weeks prior to treatment;
  14. Pregnant or lactating women.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Michael Schickler, PhD +972 3 933 3121 trials@purple-biotech.com
Contact: Naomi Yama, RN, BSN +972 3 933 3121 trials@purple-biotech.com
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04731467
Other Study ID Numbers  ICMJE FW-2020-1
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Purple Biotech Ltd. ( Famewave Ltd. )
Study Sponsor  ICMJE Famewave Ltd.
Collaborators  ICMJE Bristol-Myers Squibb
Investigators  ICMJE
Study Director: Michael Schickler, PhD Famewave Ltd.
PRS Account Purple Biotech Ltd.
Verification Date March 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP